valuation of prophylactic effect of oral Transamine on severity of bleeding

Phase 3

Recruiting

• Conditions: Von Wilbirand-Bairnald Solaire-Glynsman-Hemophilia.; https://icd.who.int/browse10/2019/en#/D69.1; D69.1

• Registration Number: IRCT20200812048378N1
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 September 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

1. Approved hereditary platelet dysfunction
2. Age over 2 and under 18 years
3. Lack of sensitivity to transamines
4. No history of thromboembolism

Exclusion Criteria

Dissatisfaction to continue the study
Death of patients for any reason during the examination period
Lack of regular visits to the clinic for follow-up treatment

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bleeding in children with hereditary dysfunction. Timepoint: 30, 60 and 90 days after starting the drug. Method of measurement: Intensity and frequency of hereditary bleeding according to ISTH bleeding score before intervention, end of one month, end of two months and end of three months after intervention.